ArticleLangenbeck's archives of surgery2026
Early postoperative serum IL-6 may contribute to risk stratification for pancreas-specific complications after pancreatic resection.
Article in Langenbeck's archives of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIL-6 level in serum has been shown to have predictive value for postoperative infectious complications and prognostic value in acute pancreatitis. Evidence on its role after pancreatic resection is limited. The aim of the study was to analyse the predictive role of early postoperative serum IL-6 regarding complications after pancreatic resection.
methodsA retrospective analysis of patients with pancreatic resection at a tertiary German centre was performed. All IL-6 values per patient within 48 h after resection were delineated. Values at fixed postoperative time points were interpolated between each patient's measurements and, beyond them, predicted from a linear mixed-effects model. Receiver operating characteristic curve analysis was performed, and optimal time and cut-off points for prediction of postoperative pancreatic fistula (POPF), postpancreatectomy acute pancreatitis (PPAP) and overall complications were set out.
resultsOut of 316 patients, 157 patients with more than one IL-6 value were included. IL-6 at 36 h after resection showed the best diagnostic performance for all three endpoints. For PPAP B/C, the AUC was 0.800 (95% CI 0.685-0.916) at a cut-off of 296 pg/ml (sensitivity 62%, specificity 80%, PPV 26%, NPV 95%), and for POPF B/C 0.715 (0.632-0.798) at 192 pg/ml (sensitivity 70%, specificity 59%, PPV 52%, NPV 76%). Discrimination for major complications (Clavien-Dindo ≥ 3b) was weaker, with an AUC of 0.636 (0.539-0.733) at 208 pg/ml (sensitivity 55%, specificity 62%, PPV 44%, NPV 73%).
conclusionSerum IL-6 within 48 h after pancreatic resection could be useful in risk assessment for pancreas-specific complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.